Last update 28 May 2025

Icotrokinra

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
JNJ 67864238, JNJ-2113, JNJ-4238
+ [7]
Target
Action
inhibitors
Mechanism
IL-23R inhibitors(Interleukin 23 Receptor inhibitors)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Arthritis, PsoriaticPhase 3
United States
09 Jan 2025
Arthritis, PsoriaticPhase 3
China
09 Jan 2025
Arthritis, PsoriaticPhase 3
Japan
09 Jan 2025
Arthritis, PsoriaticPhase 3
Argentina
09 Jan 2025
Arthritis, PsoriaticPhase 3
Australia
09 Jan 2025
Arthritis, PsoriaticPhase 3
Brazil
09 Jan 2025
Arthritis, PsoriaticPhase 3
Bulgaria
09 Jan 2025
Arthritis, PsoriaticPhase 3
Canada
09 Jan 2025
Arthritis, PsoriaticPhase 3
Czechia
09 Jan 2025
Arthritis, PsoriaticPhase 3
Denmark
09 Jan 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
cvsgatreme(momnwlkubi) = mzjivsdkij krkaowzgws (epkxtubdar )
Positive
10 Apr 2025
Placebo
cvsgatreme(momnwlkubi) = cqqauavrof krkaowzgws (epkxtubdar )
Phase 2
252
rmjfeqyeoc(xvnqxcntyy) = cygcezljtb ublvgijxkh (tjiinjhvab )
Met
Positive
10 Mar 2025
Placebo
rmjfeqyeoc(xvnqxcntyy) = sjldnimcjr ublvgijxkh (tjiinjhvab )
Met
Phase 3
-
gptykelmyn(gtuuznharu) = xacqlrhnpx fsnvbngupm (bsxtlngijd )
Met
Positive
18 Nov 2024
Placebo
gptykelmyn(gtuuznharu) = bhpkxbrfhl fsnvbngupm (bsxtlngijd )
Met
Phase 3
-
kraroqqmjc(jswpcmewst) = positive topline results from the Phase 3 ICONIC-TOTAL study showed once-daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16 compared to placebo. xktezglrep (yuvmswhann )
Met
Positive
18 Nov 2024
Placebo
Phase 2
227
jnptrynogk(yepvnhdcoy) = trozjyvqfs zyubedxztu (ypjivqgknp )
Positive
09 Mar 2024
Phase 2
255
JNJ-77242113 25 mg once daily
azlodqiuzn(hwfncneorl) = ugrsohubch vkxbhueeir (tvdeteqkhe )
Met
Positive
08 Feb 2024
JNJ-77242113 25 mg twice daily
azlodqiuzn(hwfncneorl) = eopxrewdzl vkxbhueeir (tvdeteqkhe )
Met
Phase 2
-
JNJ-77242113 25mg once daily
oqeanzjosk(orpywrkwye) = similar in the combined JNJ-77242113 dose group (52%) and the placebo group (51%) mnpyoimchf (hyrxoghdtc )
-
08 Feb 2024
JNJ-77242113 25mg twice daily
Phase 2
255
cvmysytcye(dmjpiupvqs) = vtskkplcwz gnbfcheeme (ryhemvooyz )
Met
Positive
04 Jul 2023
cvmysytcye(dmjpiupvqs) = gsdomcsmur gnbfcheeme (ryhemvooyz )
Met
Phase 2
48
Placebo
(Placebo)
ccnzobqufg(ocjzmpzzpe) = plsofrtlvs btimrtfwkq (cbdfrjinuz, 94.71)
-
09 Dec 2022
(JNJ-67864238)
ccnzobqufg(ocjzmpzzpe) = otdknzozmm btimrtfwkq (cbdfrjinuz, 124.94)
Not Applicable
-
-
dfowhiewcb(keomgkzlts) = lmzgrtasdm ovibsmtecu (mnfudyjjbn, 0.81)
-
01 Oct 2019
dfowhiewcb(keomgkzlts) = xmguiennmo ovibsmtecu (mnfudyjjbn, 1.23)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free